Repaglinide Teva 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
IB/0015 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/12/2021 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
amended 
on 
SmPC, Annex 
II, Labelling 
and PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IA/0014 
A.7 - Administrative change - Deletion of 
16/02/2021 
manufacturing sites 
Annex II and 
PL 
IAIN/0013/G 
This was an application for a group of variations. 
22/01/2020 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0012 
A.5.a - Administrative change - Change in the name 
14/09/2016 
28/04/2017 
Annex II and 
and/or address of a manufacturer/importer 
responsible for batch release 
PL 
IB/0011/G 
This was an application for a group of variations. 
25/05/2016 
28/04/2017 
SmPC, Annex 
II, Labelling 
and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0010/G 
This was an application for a group of variations. 
12/11/2015 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
T/0009 
Transfer of Marketing Authorisation from Teva 
03/11/2014 
21/11/2014 
SmPC, 
Pharma B.V. (Utrecht) to Teva B.V. (Haarlem). 
Transfer of Marketing Authorisation 
Labelling and 
PL 
R/0008 
Renewal of the marketing authorisation. 
25/04/2014 
19/06/2014 
This is a renewal of the Marketing Authorisation for a 
IA/0007 
B.II.b.4.a - Change in the batch size (including batch 
25/02/2013 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the currently approved batch size 
generic product.  
During the renewal period no significant information has 
arisen that alters the overall assessment of the benefit/risk 
balance of Repaglinide Teva. 
The CHMP recommends that the renewal be granted with 
unlimited validity. 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0006/G 
This was an application for a group of variations. 
14/12/2012 
18/12/2013 
Annex II and 
PL 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer of the finished 
product, including quality control sites (excluding 
manufacturer for batch release) 
B.II.b.2.b.1 - Change to batch release arrangements 
and quality control testing of the FP - Not including 
batch control/testing 
IB/0005 
Updated section 4.5 of the SmPC in order to include 
28/06/2012 
29/10/2012 
SmPC, Annex 
II, Labelling 
and PL 
a new drug-drug interaction with deferasirox. Section 
2 of the Package Leaflet has been updated 
accordingly. 
The Product Information has also been updated in 
line with the latest QRD template (version 8). 
The MAH also took this opportunity to update some 
of the contact details for local representatives in the 
Package Leaflet (Estonia, Finland, Germany, Iceland, 
Ireland, Norway and Romania). 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IA/0004 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
24/04/2012 
n/a 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0003/G 
This was an application for a group of variations. 
02/08/2011 
n/a 
Annex II and 
PL 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer of the finished 
product, including quality control sites (excluding 
manufacturer for batch release) 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.a - Change to batch release arrangements 
and quality control testing of the FP - Replacement 
or addition of a site where batch control/testing 
takes place 
B.II.b.2.b.1 - Change to batch release arrangements 
and quality control testing of the FP - Not including 
batch control/testing 
B.II.b.3.a - Change in the manufacturing process of 
the finished product - Minor change in the 
manufacturing process of an immediate release solid 
oral dosage form or oral solutions 
N/0002 
Minor change in labelling or package leaflet not 
18/03/2011 
n/a 
Annex II and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IA/0001 
To replace a secondary packaging site for 
18/12/2009 
n/a 
Repaglinide Teva finished product. 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA_07_a_Replacement/add. of manufacturing site: 
Secondary packaging site 
Page 6/6 
 
 
 
 
 
 
 
